104 related articles for article (PubMed ID: 38866015)
1. Cancer mutational signatures identification in clinical assays using neural embedding-based representations.
Yaacov A; Ben Cohen G; Landau J; Hope T; Simon I; Rosenberg S
Cell Rep Med; 2024 Jun; ():101608. PubMed ID: 38866015
[TBL] [Abstract][Full Text] [Related]
2. APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas.
Selenica P; Marra A; Choudhury NJ; Gazzo A; Falcon CJ; Patel J; Pei X; Zhu Y; Ng CKY; Curry M; Heller G; Zhang YK; Berger MF; Ladanyi M; Rudin CM; Chandarlapaty S; Lovly CM; Reis-Filho JS; Yu HA
Ann Oncol; 2022 Dec; 33(12):1284-1295. PubMed ID: 36089134
[TBL] [Abstract][Full Text] [Related]
3. Comprehensively Exploring the Mutational Landscape and Patterns of Genomic Evolution in Hypermutated Cancers.
Lin PC; Yeh YM; Hsu HP; Chan RH; Lin BW; Chen PC; Pan CC; Hsu KF; Hsiao JR; Shan YS; Shen MR
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503126
[TBL] [Abstract][Full Text] [Related]
4. Clinical and genomic characterization of mutational signatures across human cancers.
Liao J; Bai J; Pan T; Zou H; Gao Y; Guo J; Xu Q; Xu J; Li Y; Li X
Int J Cancer; 2023 Apr; 152(8):1613-1629. PubMed ID: 36533638
[TBL] [Abstract][Full Text] [Related]
5. APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer.
Shi MJ; Meng XY; Lamy P; Banday AR; Yang J; Moreno-Vega A; Chen CL; Dyrskjøt L; Bernard-Pierrot I; Prokunina-Olsson L; Radvanyi F
Eur Urol; 2019 Jul; 76(1):9-13. PubMed ID: 30975452
[TBL] [Abstract][Full Text] [Related]
6. Elevated APOBEC mutational signatures implicate chronic injury in etiology of an aggressive head-and-neck squamous cell carcinoma: a case report.
Patel J; den Breems NY; Tuluc M; Johnson J; Curry JM; South AP; Cho RJ
J Med Case Rep; 2021 Apr; 15(1):252. PubMed ID: 33926553
[TBL] [Abstract][Full Text] [Related]
7. Mutational signatures in squamous cell carcinoma of the lung.
Osoegawa A; Takada K; Okamoto T; Sato S; Nagahashi M; Tagawa T; Tsuchida M; Oki E; Okuda S; Wakai T; Mori M
J Thorac Dis; 2021 Feb; 13(2):1075-1082. PubMed ID: 33717580
[TBL] [Abstract][Full Text] [Related]
8. A semiparametric kernel independence test with application to mutational signatures.
Lee D; Zhu B
J Am Stat Assoc; 2021; 116(536):1648-1661. PubMed ID: 35515712
[TBL] [Abstract][Full Text] [Related]
9. Mutational signatures reveal ternary relationships between homologous recombination repair, APOBEC, and mismatch repair in gynecological cancers.
Farmanbar A; Firouzi S; Kneller R; Khiabanian H
J Transl Med; 2022 Feb; 20(1):65. PubMed ID: 35109853
[TBL] [Abstract][Full Text] [Related]
10. ScalpelSig Designs Targeted Genomic Panels from Data to Detect Activity of Mutational Signatures.
Franzese N; Fan J; Sharan R; Leiserson MDM
J Comput Biol; 2022 Jan; 29(1):56-73. PubMed ID: 34986026
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive genomic and clinical analyses identify APOBEC mutational signatures as a brain metastasis risk factor in lung adenocarcinoma patients.
Li Q; Jiang M; Hong S; Yang J; Wu X; Pang J; Chen Y; Zhao X; Ding X
Transl Oncol; 2024 May; 43():101921. PubMed ID: 38402722
[TBL] [Abstract][Full Text] [Related]
12. Integrative genomic analysis identifies associations of molecular alterations to APOBEC and BRCA1/2 mutational signatures in breast cancer.
Trevino V
Mol Genet Genomic Med; 2019 Aug; 7(8):e810. PubMed ID: 31294536
[TBL] [Abstract][Full Text] [Related]
13. Unveiling the interplay between mutational signatures and tumor microenvironment: a pan-cancer analysis.
Luo LZ; Li S; Wei C; Ma J; Qian LM; Chen YX; Wang SX; Zhao Q
Front Immunol; 2023; 14():1186357. PubMed ID: 37283742
[TBL] [Abstract][Full Text] [Related]
14. APOBEC mutational signature predicts prognosis and immunotherapy response in nonsmoking patients with lung adenocarcinoma.
Ma J; Yang X; Zhang J; Antonoff MB; Wu Q; Ji H
Transl Lung Cancer Res; 2023 Mar; 12(3):580-593. PubMed ID: 37057114
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic and prognostic insights from the analysis of cancer mutational signatures.
Brady SW; Gout AM; Zhang J
Trends Genet; 2022 Feb; 38(2):194-208. PubMed ID: 34483003
[TBL] [Abstract][Full Text] [Related]
16. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
[TBL] [Abstract][Full Text] [Related]
17. APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer.
Natesan D; Zhang L; Martell HJ; Jindal T; Devine P; Stohr B; Espinosa-Mendez C; Grenert J; Van Ziffle J; Joseph N; Umetsu S; Onodera C; Turski M; Chan E; Desai A; Aggarwal R; Wong A; Porten S; Chou J; Friedlander T; Fong L; Small EJ; Sweet-Cordero A; Koshkin VS
Front Oncol; 2022; 12():816706. PubMed ID: 35321431
[TBL] [Abstract][Full Text] [Related]
18. Mutational signatures reveal mutual exclusivity of homologous recombination and mismatch repair deficiencies in colorectal and stomach tumors.
Farmanbar A; Kneller R; Firouzi S
Sci Data; 2023 Jul; 10(1):423. PubMed ID: 37393385
[TBL] [Abstract][Full Text] [Related]
19. APOBEC3 mutational signatures are associated with extensive and diverse genomic instability across multiple tumour types.
Jakobsdottir GM; Brewer DS; Cooper C; Green C; Wedge DC
BMC Biol; 2022 May; 20(1):117. PubMed ID: 35597990
[TBL] [Abstract][Full Text] [Related]
20. Mutational signature analysis in non-small cell lung cancer patients with a high tumor mutational burden.
van den Heuvel GRM; Kroeze LI; Ligtenberg MJL; Grünberg K; Jansen EAM; von Rhein D; de Voer RM; van den Heuvel MM
Respir Res; 2021 Nov; 22(1):302. PubMed ID: 34819052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
